THE BioMed Co., Ltd. (KOSDAQ:214610)
South Korea
· Delayed Price · Currency is KRW 4,610.00
-280.00 (-5.73%)
At close: May 8, 2025, 3:30 PM KST
THE BioMed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 4,640 | 5,367 | 16,111 | 30,302 | 45,672 | Upgrade
|
| Other Revenue | 0 | 0 | - | -0 | - | Upgrade
|
| Revenue | 4,640 | 5,367 | 16,111 | 30,302 | 45,672 | Upgrade
|
| Revenue Growth (YoY) | -13.55% | -66.69% | -46.83% | -33.65% | 1014.48% | Upgrade
|
| Cost of Revenue | 10,660 | 12,339 | 16,690 | 15,599 | 24,808 | Upgrade
|
| Gross Profit | -6,020 | -6,971 | -578.73 | 14,704 | 20,864 | Upgrade
|
| Selling, General & Admin | 8,354 | 6,904 | 11,875 | 12,449 | 10,072 | Upgrade
|
| Research & Development | 3,184 | 4,036 | 7,454 | 7,831 | 6,150 | Upgrade
|
| Other Operating Expenses | 521.49 | 191.61 | 279.94 | 196.69 | 168.1 | Upgrade
|
| Operating Expenses | 15,949 | 13,012 | 25,343 | 25,562 | 17,399 | Upgrade
|
| Operating Income | -21,969 | -19,983 | -25,922 | -10,859 | 3,466 | Upgrade
|
| Interest Expense | -1,365 | -3,175 | -2,425 | -574.75 | -694.21 | Upgrade
|
| Interest & Investment Income | 675.55 | 426.08 | 310.91 | 82.3 | 48.43 | Upgrade
|
| Currency Exchange Gain (Loss) | 119.6 | 5.29 | 494.91 | 925.55 | -866.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 263.16 | -361.25 | -2,357 | -172.32 | -7,694 | Upgrade
|
| EBT Excluding Unusual Items | -22,276 | -23,088 | -29,898 | -10,598 | -5,741 | Upgrade
|
| Gain (Loss) on Sale of Investments | -5,956 | -3,802 | -7,764 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 313.83 | 2,063 | -192.28 | -0.55 | - | Upgrade
|
| Asset Writedown | -848.89 | -739.18 | -1,078 | - | -48.08 | Upgrade
|
| Other Unusual Items | -568.9 | -242.39 | - | - | - | Upgrade
|
| Pretax Income | -29,335 | -25,808 | -38,932 | -10,598 | -5,789 | Upgrade
|
| Income Tax Expense | -1,236 | -12.97 | -12.86 | -12.97 | -12.97 | Upgrade
|
| Earnings From Continuing Operations | -28,100 | -25,795 | -38,919 | -10,585 | -5,776 | Upgrade
|
| Earnings From Discontinued Operations | -3,704 | - | - | - | - | Upgrade
|
| Net Income to Company | -31,803 | -25,795 | -38,919 | -10,585 | -5,776 | Upgrade
|
| Minority Interest in Earnings | 954.57 | 20.62 | 26.65 | 10.18 | 0.07 | Upgrade
|
| Net Income | -30,849 | -25,774 | -38,893 | -10,575 | -5,776 | Upgrade
|
| Net Income to Common | -30,849 | -25,774 | -38,893 | -10,575 | -5,776 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 2 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 76.24% | 12.70% | 0.19% | 25.24% | 22.97% | Upgrade
|
| EPS (Basic) | -7073.32 | -10415.35 | -17712.59 | -4825.15 | -3300.46 | Upgrade
|
| EPS (Diluted) | -7073.32 | -10420.00 | -17712.59 | -4825.15 | -3300.46 | Upgrade
|
| Free Cash Flow | -11,652 | -11,744 | -15,631 | -11,441 | -24,440 | Upgrade
|
| Free Cash Flow Per Share | -2671.58 | -4745.83 | -7118.61 | -5220.26 | -13965.96 | Upgrade
|
| Gross Margin | -129.73% | -129.88% | -3.59% | 48.52% | 45.68% | Upgrade
|
| Operating Margin | -473.46% | -372.30% | -160.89% | -35.83% | 7.59% | Upgrade
|
| Profit Margin | -664.83% | -480.20% | -241.40% | -34.90% | -12.65% | Upgrade
|
| Free Cash Flow Margin | -251.10% | -218.81% | -97.02% | -37.76% | -53.51% | Upgrade
|
| EBITDA | -19,884 | -17,673 | -23,075 | -8,419 | 5,242 | Upgrade
|
| EBITDA Margin | - | - | -143.22% | -27.78% | 11.48% | Upgrade
|
| D&A For EBITDA | 2,085 | 2,310 | 2,847 | 2,439 | 1,776 | Upgrade
|
| EBIT | -21,969 | -19,983 | -25,922 | -10,859 | 3,466 | Upgrade
|
| EBIT Margin | - | - | -160.89% | -35.83% | 7.59% | Upgrade
|
| Advertising Expenses | 739.04 | 557.28 | 1,002 | 2,891 | 1,030 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.